RecruitingPhase 3NCT06858579

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of DNTH103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

Sponsor

Dianthus Therapeutics

Enrollment

256 participants

Start Date

Feb 10, 2025

Study Type

INTERVENTIONAL

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy

Summary

The purpose of this Phase 3 study is to demonstrate the efficacy of claseprubart (DNTH103) as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Claseprubart, a drug called Claseprubart, and others for people with chronic inflammatory demyelinating polyneuropathy. The study is currently recruiting participants at 180 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGClaseprubart

IV Infusion

DRUGClaseprubart

SC injection

DRUGPlacebo

SC injection

Locations(192)

Clinical Study Site

Birmingham, Alabama, United States

Clinical Study Site

Phoenix, Arizona, United States

Clinical Study Site

Scottsdale, Arizona, United States

Clinical Study Site

Los Angeles, California, United States

Clinical Study Site

San Francisco, California, United States

Clinical Study Site

San Francisco, California, United States

Cinical Study Site

New Haven, Connecticut, United States

Clinical Study Site

Washington D.C., District of Columbia, United States

Clinical Study Site

Maitland, Florida, United States

Clinical Study Site

Tampa, Florida, United States

Clinical Study Site

Honolulu, Hawaii, United States

Clinical Study Site

Chicago, Illinois, United States

Clinical Study Site

Edwardsville, Illinois, United States

Clinical Study Site

Indianapolis, Indiana, United States

Clinical Study Site

Kansas City, Kansas, United States

Clinical Study Site

Burlington, Massachusetts, United States

Clinical Study Site

East Lansing, Michigan, United States

Clinical Study Site

Omaha, Nebraska, United States

Cinical Study Site

Lebanon, New Hampshire, United States

Clinical Study Site

New York, New York, United States

Clinical Study Site

New York, New York, United States

Clinical Study Site

Cincinnati, Ohio, United States

Clinical Study Site

Columbus, Ohio, United States

Clinical Study Site

Portland, Oregon, United States

Cinical Study Site

Nashville, Tennessee, United States

Clinical Study Site

Dallas, Texas, United States

Clinical Study Site

Denton, Texas, United States

Cinical Study Site

Houston, Texas, United States

Texas Locations

Houston, Texas, United States

Clinical Study Site

Round Rock, Texas, United States

Clinical Study Site

Sugar Land, Texas, United States

Clinical Study Site

Seattle, Washington, United States

Cinical Study Site

Buenos Aires, Buenos Aires, Argentina

Cinical Study Site

Rosario, Santa Fe Province, Argentina

Cinical Study Site #3

Buenos Aires, Argentina

Cinical Study Site #4

Buenos Aires, Argentina

Cinical Study Site

Buenos Aires, Argentina

Clinical Study Site #2

Buenos Aires, Argentina

Clinical Study Site

Buenos Aires, Argentina

Cinical Study Site #2

San Miguel de Tucumán, Argentina

Clinical Study Site

San Miguel de Tucumán, Argentina

Cinical Study Site

Liverpool, New South Wales, Australia

Clinical Study Site

Randwick, New South Wales, Australia

Cinical Study Site

Saint Leonards, New South Wales, Australia

Cinical Study Site

Sydney, New South Wales, Australia

Cinical Study Site

Southport, Queensland, Australia

Clinical Study Site

Melbourne, Victoria, Australia

Cinical Study Site

Anderlecht, Brussels Capital, Belgium

Cinical Study Site

Brussels, Belgium

Cinical Study Site

Rio de Janeiro, Rio de Janeiro, Brazil

Clinical Study Site

Campinas, São Paulo, Brazil

Cinical Study Site

Natal, Brazil

Cinical Study Site

Porto Alegre, Brazil

Cinical Study Site

Salvador, Brazil

Cinical Study Site

São Paulo, Brazil

Cinical Study Site

São Paulo, Brazil

Cinical Study Site

São Paulo, Brazil

Cinical Study Site

Sofia, Bulgaria

Clinical Study Site

Sofia, Bulgaria

Clinical Study Site

Hefei, Anhui, China

Clinical Study Site

Guangzhou, Guangdong, China

Clinical Study Site

Changsha, Hu'Nan, China

Clinical Study Site

Changsha, Hu'Nan, China

Clinical Study Site

Wuhan, Hubei, China

Clinical Study Site

Chifeng, Inner Mongolia, China

Clinical Study Site

Suzhou, Jiangsu, China

Clinical Study Site

Beijing, China

Clinical Study Site

Beijing, China

Clinical Study Site

Chengdu, China

Clinical Study Site

Fujian, China

Clinical Study Site

Guangdong, China

Clinical Study Site

Guangzhou, China

Clinical Study Site

Jilin City, China

Clinical Study Site

Shanghai, China

Clinical Study Site

Shanghai, China

Clinical Study Site

Sichuan, China

Clinical Study Site

Taiyuan, China

Clinical Study Site

Wuhan, China

Cinical Study Site

Medellín, Antioquia, Colombia

Cinical Study Site

Antioquia, Colombia

Cinical Study Site

Medellín, Colombia

Cinical Study Site

Osijek, Croatia

Clinical Study Site

Aarhus, Denmark

Clinical Study Site

Copenhagen, Denmark

Clinical Study Site

Bordeaux, France

Cinical Study Site

Brest, France

Clinical Study Site

Bron, France

Clinical Study Site

Clermont-Ferrand, France

Clinical Study Site

Libourne, France

Clinical Study Site

Marseille, France

Clinical Study Site

Nice, France

Clinical Study Site

Paris, France

Clinical Study Site

Paris, France

Clinical Study Site

Strasbourg, France

Cinical Study Site

Tours, France

Clinical Study Site

Tours, France

Clinical Study Site

Tbilisi, Georgia

Cinical Study Site

München, Bavaria, Germany

Clinical Study Site

Sande, Lower Saxony, Germany

Clinical Study Site

Aachen, Germany

Cinical Study Site

Greifswald, Germany

Clinical Study Site

Rüdersdorf, Germany

Clinical Study Site

Sande, Germany

Cinical Study Site

Beersheba, Israel

Cinical Study Site

Haifa, Israel

Cinical Study Site

Safed, Israel

Clinical Study Site

Bergamo, Italy

Clinical Study Site

Bologna, Italy

Cinical Study Site

Genova, Italy

Cinical Study Site

Gussago, Italy

Cinical Study Site

Milan, Italy

Cinical Study Site

Milan, Italy

Cinical Study Site

Modena, Italy

Clinical Study Site

Monza, Italy

Clinical Study Site

Pavia, Italy

Clinical Study Site

Ponderano, Italy

Clinical Study Site

Roma, Italy

Cinical Study Site

Roma, Italy

Clinical Study Site #2

Roma, Italy

Clinical Study Site

Roma, Italy

Cinical Study Site

Salerno, Italy

Cinical Study Site

Terni, Italy

Cinical Study Site

Niigata, Chubu, Japan

Cinical Study Site

Kawasaki, Kanto, Japan

Cinical Study Site

Tsukuba, Kanto, Japan

Cinical Study Site

Kurashiki, Okayama-ken, Japan

Cinical Study Site

Hirakata, Osaka, Japan

Cinical Study Site

Kawagoe, Saitama, Japan

Cinical Study Site

Ube, Yamaguchi, Japan

Cinical Study Site

Riga, Latvia

Clinical Study Site

Riga, Latvia

Cinical Study Site

Kota Kinabalu, Sabah, Malaysia

Cinical Study Site

Serdang, Salangor, Malaysia

Cinical Study Site

Kuching, Sarawak, Malaysia

Cinical Study Site

George Town, Malaysia

Cinical Study Site

Johor Bahru, Malaysia

Cinical Study Site

Kota Kinabalu, Malaysia

Cinical Study Site

Kuala Lumpur, Malaysia

Cinical Study Site

Kuala Lumpur, Malaysia

Cinical Study Site

Kuala Lumpur, Malaysia

Cinical Study Site

Kuching, Malaysia

Cinical Study Site

Serdang, Malaysia

Cinical Study Site

Sungai Buloh, Malaysia

Cinical Study Site

Amsterdam, Netherlands

Cinical Study Site

Utrecht, Netherlands

Clinical Study Site

Skopje, North Macedonia

Cinical Study Site

Batangas, Philippines

Cinical Study Site

Cebu City, Philippines

Cinical Study Site

City of Muntinlupa, Philippines

Cinical Study Site

Iloilo City, Philippines

Clinical Study Site

Bydgoszcz, Poland

Clinical Study Site

Krakow, Poland

Cinical Study Site

Lodz, Poland

Clinical Study Site

Lublin, Poland

Clinical Study Site

Lublin, Poland

Clinical Study Site

Lublin, Poland

Cinical Study Site

Warsaw, Poland

Clinical Study Site

Wroclaw, Poland

Clinical Study Site

Bucharest, Romania

Cinical Study Site

Târgu Mureş, Romania

Cinical Study Site

Belgrade, Serbia

Clinical Study Site

Belgrade, Serbia

Clinical Study Site

Kragujevac, Serbia

Clinical Study Site

Niš, Serbia

Cinical Study Site

Daegu, South Korea

Cinical Study Site

Daejeon, South Korea

Cinical Study Site #2

Seoul, South Korea

Cinical Study Site #3

Seoul, South Korea

Cinical Study Site

Seoul, South Korea

Cinical Study Site

Uijeongbu-si, South Korea

Cinical Study Site

Yangsan, South Korea

Clinical Study Site

Barcelona, Barcelona, Spain

Clinical Study Site

Alicante, Spain

Clinical Study Site

Barcelona, Spain

Cinical Study Site

Barcelona, Spain

Clinical Study Site

Bilbao, Spain

Cinical Study Site

Bangkok, Thailand

Cinical Study Site #2

Bangkok, Thailand

Cinical Study Site

Bangkok, Thailand

Cinical Study Site

Chiang Mai, Thailand

Cinical Study Site

Hat Yai, Thailand

Cinical Study Site

Khlong Luang, Thailand

Cinical Study Site

Khon Kaen, Thailand

Cinical Study Site

Khon Kaen, Thailand

Cinical Study Site

Ankara, Turkey (Türkiye)

Cinical Study Site

Bursa, Turkey (Türkiye)

Cinical Study Site

Istanbul, Turkey (Türkiye)

Cinical Study Site

Samsun, Turkey (Türkiye)

Cinical Study Site

Manchester, England, United Kingdom

Clinical Study Site

Oxford, United Kingdom

Cinical Study Site #2

Hanoi, Vietnam

Cinical Study Site

Hanoi, Vietnam

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06858579

Related Trials

A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT067523563 locations

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT07032662138 locations

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

NCT0692000482 locations

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06290141129 locations

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

NCT0709163071 locations